Lung Cancer
Conditions
Keywords
extensive stage small cell lung cancer
Brief summary
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Belotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving belotecan together with cisplatin may kill more tumor cells. PURPOSE: This phase II trial is studying how well belotecan works when given together with cisplatin in treating patients with previously untreated extensive stage small cell lung cancer.
Detailed description
OBJECTIVES: Primary * To assess the antitumor efficacy, in terms of objective response rate, of belotecan hydrochloride and cisplatin in patients with previously untreated extensive-stage small cell lung cancer. Secondary * To assess additional evidence of antitumor activity as measured by overall and progression-free survival of these patients. * To determine the safety and tolerability of this drug combination in these patients. OUTLINE: Patients receive cisplatin IV on day 1 and belotecan hydrochloride IV on days 2-4.Treatment continues in the absence of disease progression or unacceptable toxicity.
Interventions
DRUGbelotecan hydrochloride
DRUGcisplatin
Sponsors
Yonsei University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed small cell lung cancer meeting the following criteria: * Extensive-stage disease * Previously untreated disease * At least one measurable disease * No brain or leptomeningeal metastasis PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Life expectancy ≥ 12 weeks * ANC ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Hemoglobin ≥ 9.0 g/dL * Total bilirubin ≤ 1.5 mg/dL * ALT and AST ≤ 2.0 times upper normal limit (ULN) (≤ 5.0 times ULN in the presence of liver metastasis) * Alkaline phosphatase ≤ 2.0 times ULN * Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min * No active infection requiring intravenous antibiotics * No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or in situ cancer * No other severe acute or chronic medical condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration, interfere with the interpretation of study results, or make the patient ineligible for study entry, in the judgment of the investigator PRIOR CONCURRENT THERAPY: * No prior chemotherapy or radiotherapy * No other concurrent chemotherapy, radiotherapy, or immunotherapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate as assessed by RECIST criteria | 21days(1cycle) |
| Overall survival | 21days(1cycle) |
| Progression-free survival | 21days(1cycle) |
| Hematologic and non-hematologic toxicity as assessed by NCI CTCAE v3.0 | 21days(1cycle) |
Countries
South Korea
Outcome results
None listed